Dose Insider / Glossary / GIP receptor

GIP receptorWhat it is and why tirzepatide targets it

Updated November 20, 2026 路 3 min read 路 Samms 2025, Nauck 2022, MOUNJARO and ZEPBOUND labels

The GIP receptor is the protein that responds to glucose-dependent insulinotropic polypeptide, or GIP, one of the two gut hormones that make the pancreas release more insulin after a meal. Together with GLP-1, GIP is called an incretin.

20.9%SURMOUNT-1, against placebo, Tirzepatide 15 mg, weight lost by week 72
Weight lost by week 72SURMOUNT-5, adults with obesity, %SURMOUNT-5, HEAD TO HEADTirzepatide: GIP and GLP-120.2%Semaglutide: GLP-1 only13.7%SURMOUNT-1, AGAINST PLACEBOTirzepatide 15 mg20.9%Placebo3.1%Weight lost by week 72SURMOUNT-5, adults with obesity, %SURMOUNT-5, HEAD TO HEADTirzepatide: GIP and GLP-120.2%Semaglutide: GLP-1 only13.7%SURMOUNT-1, AGAINST PLACEBOTirzepatide 15 mg20.9%Placebo3.1%

The one direct trial of the two at weight-management doses.

On this page

Tirzepatide, the molecule in Mounjaro and Zepbound, activates the GIP receptor and the GLP-1 receptor at the same time. A 2022 review describes it as the first dual GIP and GLP-1 receptor agonist approved for type 2 diabetes in the United States, Europe and the United Arab Emirates; its first U.S. approval came in 2022.1,2,3

The hormone behind it

GIP and GLP-1 are both released from the gut in response to food and both raise insulin when blood sugar is high. A 2025 review by Ricardo Samms and Kyle Sloop calls GIP the primary incretin of the two.1 The tirzepatide labels say the drug is based on the GIP sequence itself, with changes that let it also activate the GLP-1 receptor and a fatty acid that binds it to albumin so that it lasts about 5 days.3

Where the receptor acts

The Samms review describes benefits of GIP receptor activation in three places:1

The Zepbound label is more cautious. It says both GIP and GLP-1 receptors are found in brain areas involved in appetite regulation, and that nonclinical studies suggest GIP may further contribute to the regulation of food intake.4 A 2022 review by Michael Nauck and David D'Alessio likewise describes both receptors as major mediators of insulin release, present in brain regions that regulate eating.2

An open debate

The role of the GIP receptor in obesity is not settled. The Samms review notes a competing idea, that blocking the receptor rather than activating it could also help with weight, because GIP may help fat tissue take up and store fat. The authors argue the opposite case, that activation is beneficial.1 Both authors work for Eli Lilly, which makes tirzepatide, and the review says so in its disclosure.1

Drug developers have explored several designs around the GLP-1 receptor, including single molecules that act on more than one receptor, as Daniel Drucker's 2018 review describes.5 Among the medicines described here, the clinical evidence for activating the GIP receptor comes from what tirzepatide itself has done in trials.

What activating both receptors showed

Across five trials in type 2 diabetes, SURPASS 1 to 5, tirzepatide at 5 to 15 mg a week lowered HbA1c by 1.24 to 2.58 points and weight by 5.4 to 11.7 kg, by the Nauck review's count.2 In SURPASS-2, against semaglutide 1 mg, weight fell by 11.2 kg on tirzepatide 15 mg against 5.7 kg.3 In the obesity trial SURMOUNT-5, weight fell by 20.2% on tirzepatide against 13.7% on semaglutide.6 In SURMOUNT-1, which compared tirzepatide with placebo over the same 72 weeks, people on 15 mg lost 20.9% of their weight against 3.1% on placebo.7

Those results show that the combination works better than semaglutide at the doses tested; they cannot show how much of the gap the GIP receptor alone explains. Our page on Ozempic and Zepbound sets out both direct trials.

Side effects

The Nauck review says tirzepatide's side effects were similar to those of the GLP-1-only medicines, mainly nausea, vomiting, diarrhea and constipation, and more common at higher doses.2 The Samms review's point that GIP receptor activation in the brain may dampen nausea is a hypothesis from laboratory work, not a finding from a head-on comparison of side effects.1

Sources

  1. Samms RJ, Sloop KW. A contemporary rationale for agonism of the GIP receptor in the treatment of obesity. Diabetes 2025;74:1326-1333. Both authors are employees of Eli Lilly and Company. doi:10.2337/dbi24-0026
  2. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol 2022;21:169. doi:10.1186/s12933-022-01604-7
  3. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 11, 12 and 14. accessdata.fda.gov
  4. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 12.1. accessdata.fda.gov
  5. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756. doi:10.1016/j.cmet.2018.03.001
  6. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. nejm.org
  7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038

Related analyses

Log each dose and see how your appetite and symptoms follow it.

Open Dose Insider